Response and mechanisms of resistance to larotrectinib and selitrectinib in metastatic undifferentiated sarcoma harboring oncogenic fusion of NTRK1

JCO Precis Oncol. 2020:4:79-90. doi: 10.1200/po.19.00287. Epub 2020 Feb 14.
No abstract available

Keywords: Drug Resistance; KRAS; NTRK translocation; Sarcoma; TRK inhibitor.